Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40


An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.

Barron CC, Alhussein MM, Kaur U, Cosman TL, Tyagi NK, Brown M, Mukherjee SD, Ellis PM, Dhesy-Thind S, Leong DP.

Curr Oncol. 2019 Aug;26(4):240-246. doi: 10.3747/co.26.4631. Epub 2019 Aug 1.


Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?

Barron CC, Tyagi NK, Alhussein MM, Mukherjee SD, Ellis PM, Dhesy-Thind S, Leong DP.

Oncologist. 2019 Nov;24(11):1405-1409. doi: 10.1634/theoncologist.2019-0263. Epub 2019 Jul 17.


Attitudes and beliefs toward the use of stereotactic body radiotherapy in oligometastatic breast cancer: A commentary on a survey of Canadian Medical Oncologists.

Donovan E, Dhesy-Thind S, Mukherjee S, Kucharczyk M, Swaminath A.

Breast J. 2019 Nov;25(6):1222-1224. doi: 10.1111/tbj.13435. Epub 2019 Jul 1.


A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy.

Mackett K, Dhesy-Thind S, Donovan EK, Mukherjee S, Swaminath A, Leong DP, Voruganti S, Sussman J, Wright J, Okawara G, Fraser G, Sagar S, Bordeleau L, Ellis PM, Hirte H, Kavsak PA.

Clin Chim Acta. 2019 Aug;495:355-357. doi: 10.1016/j.cca.2019.04.083. Epub 2019 May 2. No abstract available.


MEDiastinal Irradiation and CArdio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins.

Donovan EK, Dhesy-Thind S, Swaminath A, Leong D, Pond G, Voruganti S, Sussman J, Wright JR, Okawara G, Kavsak P, Dokainish H, Fraser G, Sagar SM.

Clin Oncol (R Coll Radiol). 2019 Jul;31(7):479-485. doi: 10.1016/j.clon.2019.04.003. Epub 2019 Apr 25.


Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab.

Dhesy-Thind S, Ellis PM, Mukherjee SD, Mackett K, Bordeleau L, Kavsak PA.

Can J Cardiol. 2019 Apr;35(4):545.e1-545.e2. doi: 10.1016/j.cjca.2018.12.023. Epub 2018 Dec 28. No abstract available.


Breaking silence: a survey of barriers to goals of care discussions from the perspective of oncology practitioners.

Piggott KL, Patel A, Wong A, Martin L, Patel A, Patel M, Liu Y, Dhesy-Thind S, You JJ.

BMC Cancer. 2019 Feb 8;19(1):130. doi: 10.1186/s12885-019-5333-x.


Human Papillomavirus Status and Esophageal Adenocarcinoma: Worth a Closer Look?

Dhesy-Thind S.

JAMA Netw Open. 2018 Aug 3;1(4):e181415. doi: 10.1001/jamanetworkopen.2018.1415. No abstract available.


Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials.

Farooqi MAM, Malhotra N, Mukherjee SD, Sanger S, Dhesy-Thind SK, Ellis P, Leong DP.

PLoS One. 2018 Dec 20;13(12):e0209486. doi: 10.1371/journal.pone.0209486. eCollection 2018.


Role of allied health care professionals in goals-of-care discussions with hospitalized patients and perceived barriers: a cross-sectional survey.

Martin L, Patel A, Piggott K, Wong A, Patel A, Patel M, Liu Y, Dhesy-Thind S, Wasi P, You JJ.

CMAJ Open. 2018 Jun 22;6(2):E241-E247. doi: 10.9778/cmajo.20170162. Print 2018 Apr-Jun.


Soluble CD200 in secretory phase endometriosis endometrial venules may explain endometriosis pathophysiology and provide a novel treatment target.

Clark DA, Dmetrichuk JM, Dhesy-Thind S, Crowther MA, Arredondo JL.

J Reprod Immunol. 2018 Sep;129:59-67. doi: 10.1016/j.jri.2018.05.006. Epub 2018 May 21.


Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.

Jerzak KJ, Cockburn JG, Dhesy-Thind SK, Pond GR, Pritchard KI, Nofech-Mozes S, Sun P, Narod SA, Bane A.

Breast Cancer Res Treat. 2018 Oct;171(3):709-717. doi: 10.1007/s10549-018-4844-5. Epub 2018 Jun 18.


Clinical practice guidelines in breast cancer.

Tyagi NK, Dhesy-Thind S.

Curr Oncol. 2018 Jun;25(Suppl 1):S151-S160. doi: 10.3747/co.25.3729. Epub 2018 Jun 13. Review.


Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B.

J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16.


A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L.

Breast Cancer Res Treat. 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13.


Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.

Shenouda MM, Gillgrass A, Nham T, Hogg R, Lee AJ, Chew MV, Shafaei M, Aarts C, Lee DA, Hassell J, Bane A, Dhesy-Thind S, Ashkar AA.

Breast Cancer Res. 2017 Jul 1;19(1):76. doi: 10.1186/s13058-017-0867-9.


Reply to T.J. Powles et al.

Dhesy-Thind S, Fletcher GG, Clemons M, Van Poznak C; Cancer Care Ontario–American Society of Clinical Oncology Adjuvant Bone-Modifying Agents Panel.

J Clin Oncol. 2017 Aug 10;35(23):2720-2721. doi: 10.1200/JCO.2017.73.8567. Epub 2017 Jun 27. No abstract available.


Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH.

J Clin Oncol. 2017 Jun 20;35(18):2062-2081. doi: 10.1200/JCO.2016.70.7257. Epub 2017 Mar 6. Review.


Targeted metabolomics in colorectal cancer: a strategic approach using standardized laboratory tests of the blood and urine.

Jerzak KJ, Laureano M, Elsharawi R, Kavsak P, Chan KK, Dhesy-Thind SK, Zbuk K.

Hypoxia (Auckl). 2017 May 24;5:61-66. doi: 10.2147/HP.S127560. eCollection 2017.


Uptake of a 21-gene expression assay in breast cancer practice: views of academic and community-based oncologists.

O'Brien MA, Dhesy-Thind S, Charles C, Hammond Mobilio M, Leighl NB, Grunfeld E.

Curr Oncol. 2017 Apr;24(2):e138-e145. doi: 10.3747/co.24.3395. Epub 2017 Apr 27.


Changes in expression of the CD200 tolerance-signaling molecule and its receptor (CD200R) by villus trophoblasts during first trimester missed abortion and in chronic histiocytic intervillositis.

Clark DA, Dmetrichuk JM, McCready E, Dhesy-Thind S, Arredondo JL.

Am J Reprod Immunol. 2017 Jul;78(1). doi: 10.1111/aji.12665. Epub 2017 Mar 22.


Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer.

Meyers BM, Al-Shamsi HO, Rask S, Yelamanchili R, Phillips CM, Papaioannou A, Pond GR, Jeyabalan N, Zbuk KM, Dhesy-Thind SK.

J Gastrointest Oncol. 2017 Feb;8(1):32-38. doi: 10.21037/jgo.2016.11.12.


PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.

Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, Zalewski P, Do T, Cano P, Lam WYH, Dowden S, Grassin H, Stewart J, Moore M.

J Clin Oncol. 2016 Nov 10;34(32):3914-3920. doi: 10.1200/JCO.2016.68.5776. Epub 2016 Sep 30.


Corrigendum to "The CD200 tolerance-signaling molecule and its receptor, CD200R1, are expressed in human placental villus trophoblast and in peri-implant decidua by 5 weeks' gestation" [J. Reprod. Immunol. 112 (2015) 20-23].

Clark DA, Arredondo JL, Dhesy-Thind S.

J Reprod Immunol. 2016 Sep;117:89-90. doi: 10.1016/j.jri.2016.05.007. Epub 2016 Jun 7. No abstract available.


Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.

Rayson D, Lupichuk S, Potvin K, Dent S, Shenkier T, Dhesy-Thind S, Ellard SL, Prady C, Salim M, Farmer P, Allo G, Tsao MS, Allan A, Ludkovski O, Bonomi M, Tu D, Hagerman L, Goodwin R, Eisenhauer E, Bradbury P.

Breast Cancer Res Treat. 2016 May;157(1):109-16. doi: 10.1007/s10549-016-3812-1. Epub 2016 Apr 26.


The CD200 tolerance-signaling molecule and its receptor, CD200R1, are expressed in human placental villus trophoblast and in peri-implant decidua by 5 weeks' gestation.

Clark DA, Arredondo JL, Dhesy-Thind S.

J Reprod Immunol. 2015 Nov;112:20-3. doi: 10.1016/j.jri.2015.05.005. Epub 2015 Jun 16.


The Receptor for the CD200 Tolerance-Signaling Molecule Associated with Successful Pregnancy is Expressed by Early-Stage Breast Cancer Cells in 80% of Patients and by Term Placental Trophoblasts.

Clark DA, Dhesy-Thind S, Arredondo JL, Ellis PM, Ramsay JA.

Am J Reprod Immunol. 2015 Nov;74(5):387-91. doi: 10.1111/aji.12403. Epub 2015 May 24.


(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.

You JJ, Cline KJ, Gu CS, Pritchard KI, Dayes IS, Gulenchyn KY, Inculet RI, Dhesy-Thind SK, Freeman MA, Chan AM, Julian JA, Levine MN.

Br J Cancer. 2015 May 26;112(11):1737-43. doi: 10.1038/bjc.2015.151. Epub 2015 May 5.


Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications.

Jerzak KJ, Cockburn J, Pond GR, Pritchard KI, Narod SA, Dhesy-Thind SK, Bane A.

Breast Cancer Res Treat. 2015 Jan;149(1):293-301. doi: 10.1007/s10549-014-3235-9. Epub 2014 Dec 27.


Canadian Institutes of Health Research dissemination grant on high-sensitivity cardiac troponin.

Kavsak PA, Jaffe AS, Hickman PE, Mills NL, Humphries KH, McRae A, Devereaux PJ, Lamy A, Whitlock R, Dhesy-Thind SK, Potter JM, Worster A.

Clin Biochem. 2014 Nov;47(16-17):155-7. doi: 10.1016/j.clinbiochem.2014.10.002. Epub 2014 Oct 7. No abstract available.


The CD200-tolerance signaling molecule associated with pregnancy success is present in patients with early-stage breast cancer but does not favor nodal metastasis.

Clark DA, Dhesy-Thind S, Ellis P, Ramsay J.

Am J Reprod Immunol. 2014 Nov;72(5):435-9. doi: 10.1111/aji.12297. Epub 2014 Jul 18.


Cardiac and inflammation biomarker profile after initiation of adjuvant trastuzumab therapy.

Dhesy-Thind S, Kumar V, Snider-McNair A, Shortt C, Mukherjee SD, Ellis P, Pond GR, Kavsak PA.

Clin Chem. 2013 Jan;59(1):327-9. doi: 10.1373/clinchem.2012.192419. Epub 2012 Sep 20. No abstract available.


Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer.

Nofech-Mozes S, Vella ET, Dhesy-Thind S, Hanna WM.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):684-96. doi: 10.1016/j.clon.2012.04.005. Epub 2012 May 18.


Systematic review on hormone receptor testing in breast cancer.

Nofech-Mozes S, Vella ET, Dhesy-Thind S, Hagerty KL, Mangu PB, Temin S, Hanna WM.

Appl Immunohistochem Mol Morphol. 2012 May;20(3):214-63. doi: 10.1097/PAI.0b013e318234aa12. Review.


Is colon cancer survival influenced by tumor location?

Meyers BM, Dhesy-Thind S, Zbuk K.

J Clin Oncol. 2012 May 10;30(14):1732-3; author reply 1733-4. doi: 10.1200/JCO.2011.41.3419. Epub 2012 Apr 9. No abstract available.


Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more?

Dhesy-Thind SK.

J Clin Oncol. 2012 May 1;30(13):1408-10. doi: 10.1200/JCO.2011.40.7015. Epub 2012 Feb 27. No abstract available. Erratum in: J Clin Oncol. 2012 Jul 1;30(19):2424.


Cardiac troponin testing in the acute care setting: ordering, reporting, and high sensitivity assays--an update from the Canadian society of clinical chemists (CSCC).

Kavsak PA, Allen LC, Apple FS, Booth RA, Chan PC, Delvin E, Fraser A, Fu L, Gornall D, Collier C, Hill S, Hoffman B, Huang Y, Lavoie J, Lou A, Mattman A, McQueen M, Meng QH, Oleschuk C, Pudek M, Randell E, Sohn KY, Thorlacius L, Yip PM, Dahdah N, Devereaux PJ, Dhesy-Thind S, Hotte SJ, Worster A.

Clin Biochem. 2011 Nov;44(16):1273-7. doi: 10.1016/j.clinbiochem.2011.08.001. Epub 2011 Aug 7. No abstract available.


Cardiac troponin cutoffs: the importance of assay sensitivity and the patient population.

Kavsak PA, Dhesy-Thind S.

J Clin Oncol. 2011 Mar 1;29(7):e177; author reply e178-9. doi: 10.1200/JCO.2010.32.8906. Epub 2010 Dec 28. No abstract available.


Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update).

Grunfeld E, Dhesy-Thind S, Levine M; Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

CMAJ. 2005 May 10;172(10):1319-20. No abstract available.

Supplemental Content

Loading ...
Support Center